CANDEL THERAPEUTICS INC
CADLNASDAQTrading Snapshot
- Day Range
- $10.80 – $11.00
- 52-Week Range
- $4.35 – $14.00
- Volume
- $2.23B
- Avg Volume
- $1.70B
- Shares Outstanding
- 73.3M
- Next Earnings
- Dec 12, 2026
Fundamentals Snapshot
- Annual Revenue
- $85M
- Last Q Revenue
- $21M
- P/E Ratio
- -7.7
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.19
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +54.4%
Why Investors Own CADL
- ✓High-growth profile — revenue up -3.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 32% gross margin and 21% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CANDEL THERAPEUTICS INC
CADL
StockOtter · stockotter.spaceAbout CANDEL THERAPEUTICS INC
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Candel Therapeutics: Strong Buy On Aglatimagene Prostate Cancer BLA Filing In Q4
Candel Therapeutics, Inc. is upgraded from Buy to Strong Buy, driven by phase 3 success in localized prostate cancer. The company's aglatimagene met the primary endpoint in a pivotal trial, reducing disease recurrence ri
4 Prostate Cancer Drug Stocks to Watch During Awareness Month
Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors
NEEDHAM, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEEDHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve
Candel Therapeutics to Present at September Investor Conferences
NEEDHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve d
Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes
Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO activity are restoring ca